Oncogenic Fli-1 is a potential prognostic marker for the progression of epithelial ovarian cancer

详细信息    查看全文

• 作者：Wei Song (1)
  Lingyun Hu (2)
  Wei Li (1)
  Guanjun Wang (1)
  Yan Li (1)
  Lei Yan (1)
  Ailing Li (3)
  Jiuwei Cui (1)
  
  1. Cancer center ; the First Hospital of Jilin University ; 71 Xinmin Street ; Changchun ; 130021 ; China
  2. Obstetrics and Gynecology ; the General Hospital of Chinese People鈥檚 Liberation Army ; Beijing ; China
  3. Institute of Basic Medical Sciences ; National Center of Biomedical Analysis ; 27 Tai-Ping Road ; Beijing ; 100850 ; China
  
• 关键词：Epithelial ovarian cancer (EOC) ; Fli ; 1 ; Tumor stage ; Overall survival
• 刊名：BMC Cancer
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：14
• 期：1
• 全文大小：1,218 KB
• 参考文献：1. Jemal, A, Bray, F, Center, MM, Ferlay, J, Ward, E, Forman, D (2011) Global cancer statistics. CA Cancer J Clin 61: pp. 69-90 CrossRef
  2. Siegel, R, Naishadham, D, Jemal, A (2012) Cancer statistics. CA Cancer J Clin 62: pp. 10-29 CrossRef
  3. Onda, T, Yoshikawa, H (2011) Neoadjuvant chemotherapy for advanced ovarian cancer: overview of outcomes and unanswered questions. Expert Rev Anticancer Ther 11: pp. 1053-1067 CrossRef
  4. Kurman, RJ, Visvanathan, K, Roden, R, Wu, TC, Shih, IM (2008) Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol 198: pp. 351-356 CrossRef
  5. Ben-David, Y, Bernstein, A (1991) Friend virus-induced erythroleukemia and the multistage nature of cancer. Cell 66: pp. 831-834 CrossRef
  6. Klemsz, MJ, Maki, RA, Moore, J, Hromas, R (1994) Characterization of the ets oncogene family member, fli-1. J Biol Chem 268: pp. 5769-5773
  7. Maroulakou, IG, Bowe, DB (2000) Expression and function of Ets transcription factors in mammalian development: a regulatory network. Oncogene 19: pp. 6432-6442 CrossRef
  8. Oikawa, T, Yamada, T (2003) Molecular biology of the Ets family of transcription factors. Gene 303: pp. 11-34 CrossRef
  9. Davidson, B, Reich, R, Goldberg, I, Gotlieb, WH, Kopolovic, J, Berner, A, Ben-Baruch, G, Bryne, M, Nesland, JM (2001) Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma. Clin Cancer Res 7: pp. 551-557
  10. Oikawa, T (2004) ETS transcription factors: possible targets for cancer therapy. Cancer Sci 95: pp. 626-633 CrossRef
  11. Melet, F, Motro, B, Rossi, DJ, Zhang, L, Bernstein, A (1996) Generation of a novel Fli-1 protein by gene targeting leads to a defect in thymus development and a delay in Friend virus-induced erythroleukemia. Mol Cell Biol 16: pp. 2708-2718
  12. Truong, AH, Ben-David, Y (2000) The role of Fli-1 in normal cell function and malignant transformation. Oncogene 19: pp. 6482-6489 CrossRef
  13. Spyropoulos, DD, Pharr, PN, Lavenburg, KR, Jackers, P, Papas, TS, Ogawa, M, Watson, DK (2000) Hemorrhage, impaired hematopoiesis, and lethality in mouse embryos carrying a targeted disruption of the Fli1 transcription factor. Mol Cell Biol 20: pp. 5643-5652 CrossRef
  14. Liu, F, Walmsley, M, Rodaway, A, Patient, R (2008) Fli1 acts at the top of the transcriptional network driving blood and endothelial development. Curr Biol 18: pp. 1234-1240 CrossRef
  15. Lakhanpal, GK, Vecchiarelli-Federico, LM, Li, YJ, Cui, JW, Bailey, ML, Spaner, DE, Dumont, DJ, Barber, DL, Ben-David, Y (2010) The inositol phosphatase SHIP-1 is negatively regulated by Fli-1 and its loss accelerates leukemogenesis. Blood 11: pp. 6428-6436
  16. Cui, JW, Vecchiarelli-Federico, LM, Li, YJ, Wang, GJ, Ben-David, Y (2009) Continuous Fli-1 expression plays an essential role in the proliferation and survival of F-MuLV-induced erythroleukemia and human erythroleukemia. Leukemia 23: pp. 1311-1319 CrossRef
  17. Erkizan, HV, Uversky, VN, Toretsky, JA (2010) Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing鈥檚 sarcoma. Clin Cancer Res 16: pp. 4077-4083 CrossRef
  18. Takigami, I, Ohno, T, Kitade, Y, Hara, A, Naganol, A, Kawai, G, Saitou, M, Matsuhashi, A, Yamada, K, Shimizu, K (2011) Synthetic siRNA targeting the breakpoint of EWS/Fli-1 inhibits growth of Ewing sarcoma xenografts in a mouse model. Int J Cancer 128: pp. 216-226 CrossRef
  19. Zhang, JJ, Guo, HY, Zhang, H, Wang, HB, Qian GX, XF, Hoffman, AR, Hu, JF, Ge, S (2011) Putative tumor suppressor miR-145 inhibits colon cancer cell growth by targeting oncogene Friend leukemia virus integration 1. Cancer 117: pp. 86-95 CrossRef
  20. Tamir, A, Howard, J, Higgins, RR, Li, YJ, Berger, L, Zacksenhaus, E, Reis, M, Ben-David, Y (1999) Fli-1, an Ets-related transcription factor, regulates erythropoietin- induced erythroid proliferation and differentiation: evidence for direct transcriptional repression of the Rb gene during differentiation. Mol Cell Biol 19: pp. 4452-4464
  21. Yi, H, Fujimura, Y, Ouchida, M, Prasad, DD, Rao, VN, Reddy, ES (1997) Inhibition of apoptosis by normal and aberrant Fli-1 and erg proteins involved in human solid tumors and leukemias. Oncogene 14: pp. 1259-1268 CrossRef
  22. Pereira, R, Quang, CT, Lesault, I, Dolznig, H, Beug, H, Ghysdael, J (1999) FLI-1 inhibits differentiation and induces proliferation of primary erythroblasts. Oncogene 18: pp. 1597-1608 CrossRef
  23. Li, YJ, Zhao, X, Vecchiarelli-Federico, LM, Li, Y, Datti, A, Cheng, Y, Ben-David, Y (2012) Drug-mediated inhibition of Fli-1 for the treatment of leukemia. Blood Canc J 2: pp. e54 CrossRef
  24. Jemal, A, Siegel, R, Ward, E, Hao, Y, Xu, J, Thun, MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59: pp. 225-249 CrossRef
  25. Goff, BA, Mandel, L, Muntz, HG, Melancon, CH (2000) Ovarian carcinoma diagnosis. Cancer 89: pp. 2068-2075 CrossRef
  26. Ozols, RF (2005) Treatment goals in ovarian cancer. Int J Gynecol Cancer 15: pp. S3-S11 CrossRef
  27. Kessler, M, Fotopoulou, C, Meyer, T (2013) The molecular fingerprint of high grade serous ovarian cancer reflects its fallopian tube origin. Int J Mol Sci 14: pp. 6571-6596 71" target="_blank" title="It opens in new window">CrossRef
  28. Levanon, K, Crum, C, Drapkin, R (2008) Newinsights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 26: pp. 5284-5293 CrossRef
  29. Bujor, AM, Asano, Y, Haines, P, Lafyatis, R, Trojanowska, M (2011) The C-ABL tyrosine kinase controls PKC未 induced Fli1 phosphorylation in human dermal fibroblasts. Arthritis Rheum 63: pp. 1729-1737 CrossRef
  30. Eisbacher, M, Holmes, ML, Newton, A, Hogg, PJ, Khachigian, LM, Crossley, M, Chong, BH (2003) Protein-protein interaction between Fli-1 and GATA-1 mediates synergistic expression of megakaryocyte-specific genes through cooperative DNA binding. Mol Cell Biol 23: pp. 3427-3441 CrossRef
  31. Starck, J, Cohet, N, Gonnet, C, Sarrazin, S, Doubeikovskaia, Z, Doubeikovski, A, Verger, A, Duterque-Coquillaud, M, Morle, F (2003) Functional cross-antagonism between transcription factors FLI-1 and EKLF. Mol Cell Biol 23: pp. 1390-1402 CrossRef
  32. The pre-publication history for this paper can be accessed here: 71-2407/14/424/prepub" class="a-plus-plus">http://www.biomedcentral.com/1471-2407/14/424/prepub
  
• 刊物主题：Cancer Research; Oncology; Stem Cells; Animal Models; Internal Medicine;
• 出版者：BioMed Central
• ISSN：1471-2407

文摘

Background Ovarian cancer is the most lethal gynecologic malignancy, but its etiology remains poorly understood. This study investigated the role of Fli-1 in ovarian carcinogenesis and disease survival. Methods Fli-1 protein expression was evaluated by immunohistochemistry in 104 primary epithelial ovarian cancer (EOC) patients with known follow-up data and 20 controls. Correlation between Fli-1 expression and clinical characteristics was evaluated with the logistic regression. Kaplan Meier analysis was used to assess the impact of Fli-1 expression on overall survival (OS) and disease-free survival (DFS). Cell proliferation and migration assay were used to explore the function of Fli-1 in ovarian cancer cells. Results Fli-1 was expressed in 74% cases and up-regulated in EOC tissues compared with normal control tissues (pp Conclusions This study revealed that Fli-1 played an essential role in the development and progression of ovarian cancers. Its overexpression is intimately related to malignant phenotypes and poor clinical outcome, suggesting that Fli-1 is a potential prognostic marker and therapeutic molecular target in ovarian cancer.